Merck’s COX 1 inhibitor more dangerous than Pfizer’s Celebrex... Results presented at an epidemiology conference in Bordeaux, Southern France today showed that not all COX 1 blockers are created equal. The study is the latest to suggest that Merck’s Vioxx, a $2.5B a year blockbuster drug, increases the risk of heart attacks and sudden cardiac death by 50% over Celebrex, and three times over patients not on pain killer. The study was financed by the U.S. FDA and examind the medical records of 1.4MM people.
